Skip to main content
Erschienen in: Hepatology International 2/2019

09.02.2019 | Editorial

Serum ferritin as a biomarker for NAFLD: ready for prime time?

verfasst von: Raj A. Shah, Kris V. Kowdley

Erschienen in: Hepatology International | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Excerpt

Non-alcoholic fatty liver disease (NAFLD), which is closely associated with type 2 diabetes and obesity [1, 2], is now a major cause of liver disease in many countries and has contributed to an increase in liver disease-related mortality [3, 4]. According to the most recent practice guidance published by the American Association for the Study of Liver Diseases (AASLD) [5], the diagnosis of NAFLD is established by fulfillment of two criteria: evidence of hepatic steatosis by either imaging or histology and the exclusion of secondary etiologies such as significant alcohol ingestion, use of a medication known to cause steatosis, or liver disorders resulting in secondary steatosis such as hepatitis C, Wilson’s disease, and inborn errors of metabolism. Furthermore, the differentiation of NAFLD into either non-alcoholic fatty liver (NAFL) or non-alcoholic steatohepatitis (NASH) can only be made on histologic analysis of liver tissue [5, 6]. This distinction is particularly significant as NASH is associated with an increased risk of cirrhosis, hepatocellular carcinoma, and liver-related mortality [1, 2, 4, 7]. The use of liver biopsy is restricted by cost, risk of complications, and patient discomfort [8], while diagnostic yield is limited by sampling variability and physician expertise [9]. Therefore, there is a need for non-invasive means for diagnosis of NASH and advanced fibrosis among patients with NAFLD. Imaging modalities such as ultrasonography, computed tomography, magnetic resonance imaging, and magnetic resonance spectroscopy have been reviewed by Lee et al. [10]. In addition, a number of blood-based tests have been examined for diagnosis and staging of NAFLD. Two indices that have demonstrated accuracy for detection of steatosis are the NAFLD Liver Fat Score (NLFS) and Hepatic Steatosis Index (HSI), components of which include the diagnosis of metabolic syndrome, diabetes mellitus, fasting serum insulin, AST, and AST/ALT ratio [11, 12]. The NLFS has a sensitivity of 86% and specificity of 71% at a threshold of − 0.640 [11]. The HSI has a sensitivity of 66% and specificity of 69% at a cutoff of 36 [12]. …
Literatur
1.
Zurück zum Zitat Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011;34(3):274–285CrossRef Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011;34(3):274–285CrossRef
2.
Zurück zum Zitat Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 2011;43(8):617–649CrossRef Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 2011;43(8):617–649CrossRef
4.
Zurück zum Zitat Stepanova M, Rafiq N, Makhlouf H, et al. Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD). Dig Dis Sci 2013;58(10):3017–3023CrossRefPubMed Stepanova M, Rafiq N, Makhlouf H, et al. Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD). Dig Dis Sci 2013;58(10):3017–3023CrossRefPubMed
5.
Zurück zum Zitat Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018;67(1):328–357CrossRef Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018;67(1):328–357CrossRef
6.
Zurück zum Zitat Marchesini G, Day CP, Dufour JF, et al. EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016;64(6):1388–1402CrossRef Marchesini G, Day CP, Dufour JF, et al. EASL-EASD-EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016;64(6):1388–1402CrossRef
7.
Zurück zum Zitat Stål P. Liver fibrosis in non-alcoholic fatty liver disease-diagnostic challenge with prognostic significance. World J Gastroenterol 2015;21(39):11077–11087CrossRefPubMedPubMedCentral Stål P. Liver fibrosis in non-alcoholic fatty liver disease-diagnostic challenge with prognostic significance. World J Gastroenterol 2015;21(39):11077–11087CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Procopet B, Bureau C, Métivier S, et al. Tolerance of liver biopsy in a tertiary care center: comparison of the percutaneous and the transvenous route in 143 prospectively followed patients. Eur J Gastroenterol Hepatol 2012;24(10):1209–1213CrossRefPubMed Procopet B, Bureau C, Métivier S, et al. Tolerance of liver biopsy in a tertiary care center: comparison of the percutaneous and the transvenous route in 143 prospectively followed patients. Eur J Gastroenterol Hepatol 2012;24(10):1209–1213CrossRefPubMed
9.
Zurück zum Zitat Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD. Liver biopsy. Hepatology 2009;49(3):1017–1044CrossRef Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD. Liver biopsy. Hepatology 2009;49(3):1017–1044CrossRef
11.
Zurück zum Zitat Kotronen A, Peltonen M, Hakkarainen A, et al. Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology 2009;137(3):865–872CrossRefPubMed Kotronen A, Peltonen M, Hakkarainen A, et al. Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors. Gastroenterology 2009;137(3):865–872CrossRefPubMed
12.
Zurück zum Zitat Cheung CL, Lam KS, Wong IC, Cheung BM. Non-invasive score identifies ultrasonography diagnosed non-alcoholic fatty liver disease and predicts mortality in the USA. BMC Med 2014;12(1):1–11CrossRef Cheung CL, Lam KS, Wong IC, Cheung BM. Non-invasive score identifies ultrasonography diagnosed non-alcoholic fatty liver disease and predicts mortality in the USA. BMC Med 2014;12(1):1–11CrossRef
13.
Zurück zum Zitat Ekstedt M, Hagström H, Nasr P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 2015;61(5):1547–1554CrossRefPubMed Ekstedt M, Hagström H, Nasr P, et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 2015;61(5):1547–1554CrossRefPubMed
14.
Zurück zum Zitat Xiao G, Zhu S, Xiao X, Yan L, Yang J, Wu G. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: a meta-analysis. Hepatology 2017;66(5):1486–1501CrossRefPubMed Xiao G, Zhu S, Xiao X, Yan L, Yang J, Wu G. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: a meta-analysis. Hepatology 2017;66(5):1486–1501CrossRefPubMed
15.
Zurück zum Zitat Dever JB, Mallory MA, Mallory JE, Wallace D, Kowdley KV. Phenotypic characteristics and diagnoses of patients referred to an iron overload clinic. Dig Dis Sci 2010;55(3):803–807CrossRefPubMed Dever JB, Mallory MA, Mallory JE, Wallace D, Kowdley KV. Phenotypic characteristics and diagnoses of patients referred to an iron overload clinic. Dig Dis Sci 2010;55(3):803–807CrossRefPubMed
16.
Zurück zum Zitat Kowdley KV, Belt P, Wilson LA, et al. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2012;55(1):77–85CrossRefPubMed Kowdley KV, Belt P, Wilson LA, et al. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2012;55(1):77–85CrossRefPubMed
17.
Zurück zum Zitat Maliken BD, Nelson JE, Klintworth HM, Beauchamp M, Yeh MM, Kowdley KV. Hepatic reticuloendothelial system cell iron deposition is associated with increased apoptosis in nonalcoholic fatty liver disease. Hepatology 2013;57(5):1806–1813CrossRefPubMedPubMedCentral Maliken BD, Nelson JE, Klintworth HM, Beauchamp M, Yeh MM, Kowdley KV. Hepatic reticuloendothelial system cell iron deposition is associated with increased apoptosis in nonalcoholic fatty liver disease. Hepatology 2013;57(5):1806–1813CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Kazankov K, Barrera F, Møller HJ, et al. The macrophage activation marker sCD163 is associated with morphological disease stages in patients with non-alcoholic fatty liver disease. Liver Int 2016;36(10):1549–1557CrossRefPubMed Kazankov K, Barrera F, Møller HJ, et al. The macrophage activation marker sCD163 is associated with morphological disease stages in patients with non-alcoholic fatty liver disease. Liver Int 2016;36(10):1549–1557CrossRefPubMed
20.
22.
Zurück zum Zitat Ford ES, Cogswell ME. Diabetes and serum ferritin concentration among US adults. Diabetes Care 1999;22(12):1978–1983CrossRefPubMed Ford ES, Cogswell ME. Diabetes and serum ferritin concentration among US adults. Diabetes Care 1999;22(12):1978–1983CrossRefPubMed
23.
Zurück zum Zitat Zhang GM, Xia YJ. Reference intervals of fibrosis index based on four indicators in healthy elderly Chinese. J Clin Lab Anal 2016;30(5):645–648CrossRefPubMed Zhang GM, Xia YJ. Reference intervals of fibrosis index based on four indicators in healthy elderly Chinese. J Clin Lab Anal 2016;30(5):645–648CrossRefPubMed
Metadaten
Titel
Serum ferritin as a biomarker for NAFLD: ready for prime time?
verfasst von
Raj A. Shah
Kris V. Kowdley
Publikationsdatum
09.02.2019
Verlag
Springer India
Erschienen in
Hepatology International / Ausgabe 2/2019
Print ISSN: 1936-0533
Elektronische ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-019-09934-7

Weitere Artikel der Ausgabe 2/2019

Hepatology International 2/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.